Background: Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from mutations in the a-galactosidase A (a-Gal A) gene located at Xq22.1. To determine the nature and frequency of the molecular lesions causing the classical and milder variant Fabry phenotypes and for precise carrier detection, the a-Gal A lesions in 42 unrelated Fabry hemizygotes were determined. Materials and Methods: Genomic DNA was isolated from affected probands and their family members. The seven a-galactosidase A exons and flanking intronic sequences were PCR amplified and the nucleotide sequence was determined by solid-phase direct sequenc-
INTRODUCTION
Fabry disease is an X-linked inborn error of glycosphingolipid catabolism resulting from the deficient activity of the lysosomal exoglycohydrolase, a-galactosidase A (EC 3.2.1.22; a-Gal A) (1) . Affected hemizygous males accumulate neutral glycosphingolipids with terminal a-linked galactosyl moieties particularly in the plasma and in lysosomes of blood vessels, heart, liver, and kidney. In classically affected males-who have little, if any, detectable a-Gal A activity-the onset of disease manifestations occurs in childhood or adolescence and is characterized by severe acroparesthesias, angiokeratoma, corneal opacities, and hypohidrosis. With advancing age, vascular disease of the heart, kidneys, and brain lead to early demise in adulthood. Asymptomatic or clinically milder hemizygotes with residual a-Gal A activity have an attenuated form of the disease limited to cardiac involvement (the "cardiac variants"), including cardiomegaly, typically involving the left ventricular wall and interventricular septum, EKG changes consistent with a cardiomyopathy, and myocardial infarctions (1) . The disease has a panethnic distribution with an es-timated frequency of 1 in 40,000 males. However, the frequency may be underestimated because of a lack of ascertainment and failure to diagnose mild or atypical cases (2) .
Our understanding of human a-Gal A and Fabry disease advanced markedly with the isolation and characterization of the full-length cDNA and the genomic sequences for this lysosomal hydrolase (3) (4) (5) (6) . The cDNA encodes a polypeptide of 429 residues, including a 31-amino acid signal peptide. The 12-kb a-Gal A gene contains seven exons (6) and is one of the most Alu-rich genes with about 1 Alu/kb. The gene was localized to the long arm of the X chromosome within band Xq22 by in situ hybridization (1) . The Xq22 region spans approximately 10-12 Mb of the proximal long arm of the X chromosome and also contains the a 5(IV) collagen gene (7) that is defective in Alport syndrome (8) and the agammaglobulinemia tyrosine kinase gene that is defective in Bruton's agammaglobulinemia (9) . Simple sequence repeat polymorphisms located in this region have been useful for carrier detection and prenatal diagnosis of Fabry disease by linkage analysis in informative families (10) .
A variety of mutations in the a-Gal A gene causing Fabry disease have been described, including partial gene rearrangements, small deletions and insertions, splice-junction consensus site alterations, and various coding region single base substitutions (1 1). Most mutations resulted in the classic disease phenotype; however, five missense mutations were detected in hemizygotes with the mild cardiac variant phenotype (12) (13) (14) . To date, most mutations have been confined to a single family with the exception of mutations involving CpG dinucleotides (R227Q, R227X, R342Q, and R342X), which were each found in two to six (R227X) unrelated classically affected families (14) , and N215S, which was described in three unrelated cardiac variants (15) .
To identify genotype/phenotype correlations, permit precise heterozygote detection, and facilitate selection of potential candidates for recombinant enzyme replacement trials, the nature and frequency of the a-Gal A mutations causing Fabry disease in 42 unrelated families were determined. In this study, 35 new mutations are described, including missense, nonsense, and splice-site mutations as well as small and large gene rearrangements, emphasizing the genetic heterogeneity of this disease. (Fig. 1) . The missense mutations detected in classically affected male patients included: (1) a T-to-G transversion in codon 1, predicting a methionine-tothreonine substitution (MIT); (2) a C-to-T transition at a CpG dinucleotide in codon 31, resulting in an alanine-to-valine replacement (A31V); (3) an A-to-G transition at a CpG dinucleotide in codon 46, resulting in a histidine-toarginine change (H46R); (4) an A-to-G transition in codon 86, predicting a tyrosine-to-cysteine substitution (Y86C); (5) a T-to-C transition in codon 89, predicting a leucine-to-proline replacement (L89P); (6) a T-to-C transition in codon 91, resulting in an isoleucine-to-threonine substitution (I9iT); (7) a G-to-A transition in codon 92, predicting an aspartic acid-to-tyrosine change (D92Y); (8) a G-to-A transition in codon 94, predicting an cysteine-to-tyrosine replacement (C94Y); (9) a C-to-T transition in codon 97, resulting in an arginine-to-valine replacement (A97V); (10) a G-to-C transversion in codon 100, resulting in an arginine-to-threonine substitution (R1OOT); (11) a T-to-C transition in codon 113, predicting a phenylalanine-to-leucine replacement (Fl 13L); (12) an A-to-C transversion in codon 134, predicting a tyrosine-to-serine substitution (Y134S); (13) a G-to-A transition in codon 138, predicting a glycine-to-arginine replacement (G138R); (14) a G-to-A transition in codon 143, resulting in an alanine-to-threonine substitution (A143T); (15) a T-to-G transversion in codon 148, predicting a serine-to-arginine replacement (S148R); (16) a G-to-T transversion in codon 163, resulting in a glycine-to-valine substitution (G163V); (17) a-Gal A Gene Rearrangements Eight coding-region small gene rearrangements were identified, including five deletions of one or two bases (304dell, 777dell, 1057del2, 1074del2, and 1077dell) that resulted in frameshift mutations and premature termination of the polypeptide chain; two in-frame deletions of three (1212del3) and nine bp (613del9), respectively; and one insertion of a single base (1094insl). The 304dell deletion at codon 102 in exon 2 caused a frameshift mutation and premature termination of the polypeptide chain. The 777dell mutation resulted in a frameshift in codon 259 in exon 5 with premature termination of the polypeptide chain at amino acid 268. The 1077dell mutation caused a frameshift in codon 359, the incorporation of an abnormal sequence of 30 amino acids, and resulted in premature termination of the polypeptide at residue 390. The dinucleotide deletions included the 1057de12 mutation, which caused a frameshift in codon 353 and termination of the polypeptide at residue 373 of exon 7, and the 1074del2 mutation, which resulted in a frameshift in codon 358 and premature termination at residue 373. The predicted amino acid sequences of these two frameshift mutations were totally different from the normal sequence and different from each other. The insertion mutation (1094insl) predicted a frameshift at codon 365 and premature termination of the polypeptide at codon 374. There were two in-frame deletions of three and nine bases, respectively. The 1212del3 mutation deleted the trinucleotide AAG of the normal sequence (TTA AGA AGT CAC) which predicted the in-frame deletion of an arginine at position 404. The 613del9 mutation involved the (20) . Of the 35 newly identified lesions, 61.7% were missense mutations, 3 % were splice site defects, 6% were nonsense mutations, 23.5% were small insertions or deletions, and 6% were complex mutations. No large deletions were detected. All of these mutations were confirmed in genomic DNA from other heterozygous or hemizygous family members identified by enzyme assay (data not shown). Moreover, sequencing of the entire coding region and flanking intronic sequences revealed no other alterations. All the mutations caused the classic disease manifestations, with the exception of I9 IT and F 113L, which were identified in two unrelated cardiac variants who were diagnosed at 56 and 45 years of age, and had residual (less than 10%) of normal plasma a-Gal A activity. These patients were essentially asymptomatic during most of their lives and did not experience the early classical signs and symptoms that include acroparesthesias, angiokeratoma, corneal and lenticular opacities, and hypohidrosis. The 56-year-old patient had mild proteinuria and LVH, whereas the 45-year-old patient had no renal or cardiac findings, but was ascertained to have the disease after his 71-year-old mother was diagnosed as a carrier with cardiac manifestations. Similarly, the A97V mutation was identified in an asymptomatic 39-year-old male who was diagnosed by enzymatic assay after his mother's renal biopsy showed that she had renal insufficiency and lysosomal storage consistent with Fabry disease. This male patient had no proteinuria, corneal involvement, or cardiac findings. Serial clinical evaluations of these and other cardiac variants will help delineate the natural history of the mild form of this disease. Finally, A143T was identified in a 2-month-old infant who was serendipitously found to have deficient a-Gal A activity and had no family history of Fabry disease. His mother was subsequently found to have a plasma a-Gal A activity in the carrier range (3.7 U/ml; mean normal control 10.8) and was heterozygous for the A143T mutation. There were no known affected males in this family, making genetic counseling and possible predictions of disease severity difficult.
MATERIALS AND METHODS
Of the insertions and deletions, one each occurred in exons 2, 4, and 5, while four were in exon 7. That the majority of the small gene rearrangements occurred in exon 7 is consistent with previous reports of seven other unique rearrangements in this region, indicating that exon 7 is highly susceptible to gene rearrangements. Four of the eight gene rearrangements described here occurred within 13 codons of each other, with two occurring in adjacent codons. This clustering of rearrangements indicated that a "hotspot" may exist in the region of codons 353-365 in exon 7. Analysis of this region revealed the presence of the dinucleotide repeats AT and GA, each of which occurred four times in the region. The presence of these repeats suggests a functional role in the generation of these rearrangements, which possibly result from misalignment of the repeats during DNA synthesis at the replication fork. Previously, an additional "hot-spot" for deletions was identified in exon 2 from codons 111-122 (14) .
Insights into the structure-function relations of specific a-Gal A amino acids and domains can be gained by noting the position of the point mutations causing classic or variant Fabry disease and their relative conservation in the 20 homologues encoding a-Gal A or the evolutionarily related enzyme a-N-acetylgalactosaminidase (also known as a-Gal B) (21) currently recorded in the GenBank database. For example, the two mutations involving cysteine residues (C94Y and C202Y) were highly conserved in 85% and 90% of the sequences analyzed, respectively, which indicates their probable importance in the formation of intramolecular disulfide bridges in the enzyme polypeptide. It is noteworthy that seven of the missense mutations (Y86C, L89P, 191T, D92Y, C94Y, RIOOT, and F113L) occurred in exon 2, in a highly conserved region presumed to contain residues in the active site (22) . Interestingly, six of the seven exon 2 missense mutations were highly conserved in the 20 a-Gal A and a-gal B sequences examined (ranging from 80% to 95% conserved), with the divergence occurring in the bacterial sequences. The excep-tion is the L89P mutation, which was present only in human a-Gal A and a-Gal B, and mouse a-Gal A sequences. Moreover, the mutations in the two cardiac variants were also located in exon 2 and occurred at moderately to highly conserved residues (191T, 80%; F113L, 85%); this further demonstrates the functional importance of this region.
Other mutations that occurred at highly conserved (>75%) residues were Y134S, G138R, S148R, D17OV, N263S, and W287C, which indicates their importance in the activity and/or stability of the enzyme. Certain mutations occurred in positions that were conserved residues only in mammalian a-Gal A sequences (e.g., A31V, H46R, A97V, and L89P). Presumably, substitutions occurring at less essential residues would be neutral or may retain sufficient enzymatic function to be clinically insignificant.
Both nonsense mutations Q386X and W399X occurred in classically affected patients in exon 7 toward the end of the 429 amino acid sequence, indicating that the carboxy-terminal 44 and 30 residues are critical for enzyme function. In support of this concept, one nonsense mutation (E398X) and one in-frame deletion (1208del3) in this region have been previously reported (14, 15) . Importantly, the nonsense mutations occurred at residues with the lowest degree of conservation noted for the mutations reported in this series (4/20 and 2/20 for Q386X and W399X, respectively). Another notable mutation was M1T, in which the translation initiation codon was substituted with a threonine. The next methionine was at codon 42, which, if utilized, would have deleted the entire 31-residue signal peptide, which in turn would presumably preclude targeting to the endoplasmic reticulum.
Interestingly, with the identification of two additional complex mutations in exons 1 and 2, four complex mutations have now been identified in the a-Gal A gene. Previously, complex mutations were identified in several genes, including the LDL receptor gene (23) , the HPRT gene (24) , and the serum cholinesterase gene (25) . Various mechanisms have been proposed for the generation of these mutations, including gene conversion between evolutionarily related sequences (26), or misalignment of "quasi-palindromic" sequences during DNA replication and the subsequent deletion or insertion of bases that might serve to stabilize a hairpin loop (27) . The region of the exon 1 complex mutation forms a hairpin loop structure that would be destabilized with the introduction of the five-base alteration.
Analyses of the a-Gal A and a-Gal B sequences in exons 1 and 2 do not support gene conversion as the mechanism for generation of these complex mutations.
The identification of these 35 mutations further documents the remarkable genetic heterogeneity of the a-Gal A lesions causing Fabry disease. Of the mutations identified to date, the majority (67%) have been missense mutations, whereas nonsense (10%), splicing (4%), and small and large gene rearrangements (19%) individually are less frequent occurrences (14, 28) . Mutation analysis is important for each Fabry family, as the detection of these mutations permits precise diagnosis of the heterozygous carriers of this X-linked recessive gene and provides the ability to perform molecular prenatal diagnosis. In addition, the future characterization of these mutations by crystallographic studies may provide useful structure-function information and insights for genotype/phenotype correlations.
